

Connecting via Winsock to STN at pto-stn on port 23

Welcome to STN International! Enter x:X

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	DEC	21	CAS Learning Solutions -- a new online training experience
NEWS	2	JAN	24	The new and enhanced DPCI file on STN has been released
NEWS	3	JAN	26	Improved Timeliness of CAS Indexing Adds Value to USPATFULL and USPAT2 Chemistry Patents
NEWS	4	JAN	26	Updated MeSH vocabulary, new structured abstracts, and other enhancements improve searching in STN reload of MEDLINE
NEWS	5	JAN	28	CABA will be updated weekly
NEWS	6	FEB	23	PCTFULL file on STN completely reloaded
NEWS	7	FEB	23	STN AnaVist Test Projects Now Available for Qualified Customers
NEWS	8	FEB	25	LPCI will be replaced by LDPCI
NEWS	9	MAR	07	Pricing for SELECTing Patent, Application, and Priority Numbers in the USPAT and IFI Database Families is Now Consistent with Similar Patent Databases on STN
NEWS	10	APR	26	Expanded Swedish Patent Application Coverage in CA/CAPLUS Provides More Current and Complete Information
NEWS	11	APR	28	The DWPI (files WPINDEX, WPIDS and WPIX) on STN have been enhanced with thesauri for the European Patent Classifications
NEWS	12	MAY	02	MEDLINE Improvements Provide Fast and Simple Access to DOI and Chemical Name Information
NEWS	13	MAY	12	European Patent Classification thesauri added to the INPADOC files, PCTFULL, GBFULL and FRFULL
NEWS	14	MAY	23	Enhanced performance of STN biosequence searches
NEWS	15	MAY	23	Free Trial of the Numeric Property Search Feature in PCTFULL on STN
NEWS	16	JUN	20	STN on the Web Enhanced with New Patent Family Assistant and Updated Structure Plug-In
NEWS	17	JUN	20	INPADOC databases enhanced with first page images
NEWS	18	JUN	20	PATDPA database updates to end in June 2011
NEWS	19	JUN	26	MARPAT Enhancements Save Time and Increase Usability
NEWS	20	JUL	25	STN adds Australian patent full-text database, AUPATFULL, including the new numeric search feature.
NEWS	21	AUG	01	CA Sections Added to ACS Publications Web Editions Platform
NEWS	22	AUG	16	INPADOC: Coverage of German Patent Data resumed, enhanced legal status
NEWS	23	AUG	18	Upgrade now to STN Express, Version 8.5
NEWS	24	SEP	01	CAS Journal Coverage Now Includes Ahead-of-Print Articles for More Than 100 Journal Titles
NEWS	25	SEP	01	Older Versions of STN Express to be Discontinued Beginning in March 2012
NEWS	26	SEP	09	USAN Database Updates Offer Superior Currency on STN(R)
NEWS	27	SEP	26	STN Adds Canadian Patent Full-text Database - CANPATFULL
NEWS	28	SEP	26	GEOREF and ENCOMPLIT databases were reloaded on September 24, 2011.

NEWS 29 SEP 26 Updates to the IFIPAT/IFIUDB/IFICDB databases have resumed.
NEWS 30 SEP 26 ECLA Thesaurus in CA/CAPLUS Improves Patent Searching on STN
NEWS 31 SEP 26 Access AUPATFULL and CANPATFULL databases with STN Viewer

NEWS EXPRESS 18 AUGUST 2011 CURRENT WINDOWS VERSION IS V8.5,
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:28:34 ON 06 OCT 2011

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.23	0.23

FILE 'REGISTRY' ENTERED AT 10:28:58 ON 06 OCT 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 OCT 2011 HIGHEST RN 1334472-47-7
DICTIONARY FILE UPDATES: 5 OCT 2011 HIGHEST RN 1334472-47-7

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Users\cricci\Documents\STN Express 8.4\Queries\10598281FINAL1.str



```

chain nodes :
10 17 18 19 20 21 22 23 24 25 26 27 28 32 36
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
3-32 9-10 10-11 14-36 17-18 19-20 20-21 21-22 21-23 24-25 24-26 27-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16
exact/norm bonds :
3-32 5-7 6-9 7-8 8-9 14-36 19-20 20-21 24-25 24-26
exact bonds :
9-10 10-11 17-18 21-22 21-23 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

```

G1:[@1],[@2]

G2:[@3],[@4]

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 32:CLASS 36:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1:[@1],[@2]

G2:[@3],[@4]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 10:32:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5770 TO ITERATE

100.0% PROCESSED 5770 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 110845 TO 119955

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 196.35 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 10:32:31 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 116551 TO ITERATE

100.0% PROCESSED 116551 ITERATIONS

23 ANSWERS

SEARCH TIME: 00.00.01

L3 23 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

199.41

199.64

FILE 'CAPLUS' ENTERED AT 10:32:35 ON 06 OCT 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Oct 2011 VOL 155 ISS 15
FILE LAST UPDATED: 5 Oct 2011 (20111005/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 2 L3



=> d ibib abs hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2005:1042216 CAPLUS
DOCUMENT NUMBER: 143:347050
TITLE: Preparation of
4-(5-(aminomethyl)indole-1-ylmethyl)benzamide
derivatives as opioid receptor antagonists for the
treatment of obesity
INVENTOR(S): Benesh, Dana Rae; Blanco-Pillado, Maria-Jesus
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005090303	A1	20050929	WO 2005-US7702	20050309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2558030	A1	20050929	CA 2005-2558030	20050309

EP 1751103	A1	20070214	EP 2005-725070	20050309
EP 1751103	B1	20090114		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007529523	T	20071025	JP 2007-503959	20050309
AT 420858	T	20090115	AT 2005-725070	20050309
ES 2318472	T3	20090501	ES 2005-725070	20050309
US 20070155793	A1	20070705	US 2006-598281	20060823
PRIORITY APPLN. INFO.:			US 2004-553176P	P 20040315
			WO 2005-US7702	W 20050309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:347050; MARPAT 143:347050
GI




AB Title compds. represented by the formula I [wherein X1 = CH2, CH or N; X2 = CH or N; R1, R2 = independently H, alkyl(aryl), alkenyl, etc.; R3, R3' = independently H, alkyl, alkynyl, etc.; R4, R5 = independently H, (halo)alkyl, aryl, etc.; m = 0-2; n = 0-2; p = 0-2; and pharmaceutically acceptable salts, solvates, prodrugs, enantiomers, racemates, diastereomers and diastereomeric mixture thereof] were prepared as opioid receptor antagonists. For example, II was provided in a multi-step synthesis starting from the reaction of 5-formylindole with 4-bromomethylbenzonitrile. I were tested for antagonistic activity of mu-, γ - and δ -opioid receptor in SPA-based GTP γ S binding assay, and their pharmaceutical formulations were also presented. Thus, I and their pharmaceutical compns. are useful as opioid receptor antagonists for the treatment of obesity (no data).

IT 865542-83-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide derivs. as opioid receptor antagonists for treatment of obesity)

RN 865542-83-2 CAPLUS

CN Benzamide, 4-[[5-[[[2-(2-thienyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]-
(CA INDEX NAME)




IT 865542-80-9P 865542-84-3P 865542-85-4P
 865542-86-5P 865542-87-6P 865542-88-7P
 865542-89-8P 865542-90-1P 865542-91-2P
 865542-92-3P 865542-93-4P 865542-94-5P
 865542-95-6P 865542-96-7P 865542-97-8P
 865542-98-9P 865542-99-0P 865543-00-6P
 865543-03-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide derivs. as opioid receptor antagonists for treatment of obesity)


RN 865542-80-9 CAPLUS

CN Benzamide, 4-[[5-[[[(3-methylbutyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-84-3 CAPLUS

CN Benzamide, 4-[[5-[[[(3,3-dimethylbutyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 865542-85-4 CAPLUS


CN Benzamide, 4-[[2,3-dihydro-5-[[[2-(2-thienyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 865542-86-5 CAPLUS


CN Benzamide, 4-[[2,3-dihydro-5-[[[(3-methylbutyl)amino]methyl]-1H-indol-1-

yl)methyl]- (CA INDEX NAME)




RN 865542-87-6 CAPLUS

CN Benzamide, 4-[[5-[[[(3,3-dimethylbutyl)amino]methyl]-2,3-dihydro-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 865542-88-7 CAPLUS

CN Benzamide, 4-[[5-[(hexylamino)methyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 865542-89-8 CAPLUS

CN Benzamide, 4-[[5-[[[2-(2-fluorophenyl)ethyl]amino]methyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 865542-90-1 CAPLUS


CN Benzamide, 4-[[5-[[[2-(2-fluorophenyl)ethyl]amino]methyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 865542-91-2 CAPLUS
 CN Benzamide, 4-[[5-[[[(2-hydroxyethyl)amino]methyl]-1H-indol-1-yl]methyl]-
 (CA INDEX NAME)




RN 865542-92-3 CAPLUS
 CN Benzamide, 4-[[5-[[[2-(4-methoxyphenyl)ethyl]amino]methyl]-1H-indol-1-
 yl]methyl]- (CA INDEX NAME)




RN 865542-93-4 CAPLUS
 CN Benzamide, 4-[[5-[[[(2-chloro-6-fluorophenyl)methyl]amino]methyl]-1H-indol-
 1-yl]methyl]- (CA INDEX NAME)



RN 865542-94-5 CAPLUS
 CN Benzamide, 4-[[5-[[[2-(3-pyridinyl)ethyl]amino]methyl]-1H-indol-1-
 yl]methyl]- (CA INDEX NAME)




RN 865542-95-6 CAPLUS
 CN Benzamide, 4-[[5-[[[2-(2-ethoxyphenyl)ethyl]amino]methyl]-1H-indol-1-
 yl]methyl]- (CA INDEX NAME)




RN 865542-96-7 CAPLUS

CN Benzamide, 4-[[5-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-97-8 CAPLUS

CN Benzamide, 4-[[5-[[[2-(1-cyclohexen-1-yl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-98-9 CAPLUS

CN Benzamide, 4-[[5-[[[2-(3-fluorophenyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-99-0 CAPLUS

CN Benzamide, 4-[[5-[[[2-(ethylbutyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865543-00-6 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[[4-[[[3-methylbutyl)amino]methyl]phenyl]methyl]- (CA INDEX NAME)



RN 865543-03-9 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-[[4-[[[3-methylbutyl)amino]methyl]phenyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:927166 CAPLUS

DOCUMENT NUMBER: 141:395428

TITLE: Biarylmethyl indolines, indoles, and tetrahydroquinolines, useful as serine protease inhibitors, and particularly as anticoagulants, and their preparation, pharmaceutical compositions, and use.

INVENTOR(S): Smallheer, Joanne M.; Quan, Mimi L.; Wang, Shuaige; Bisacchi, Gregory S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094372	A2	20041104	WO 2004-US11856	20040415
WO 2004094372	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040220206	A1	20041104	US 2004-824025	20040414

US 7129264 B2 20061031
 EP 1633716 A2 20060315 EP 2004-750251 20040415
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 JP 2006523716 T 20061019 JP 2006-513080 20040415
 PRIORITY APPLN. INFO.: US 2003-463452P P 20030416
 US 2004-824025 A 20040414
 WO 2004-US11856 W 20040415
 OTHER SOURCE(S): MARPAT 141:395428
 GI



AB The invention provides compds. I or stereoisomers, pharmaceutically acceptable salts or hydrates, or prodrugs thereof [wherein: W = (un)substituted CH₂CH₂, CH:CH, CH:N, or CH₂CH₂CH₂; L₁ = CH₂, CH₂CH₂, CH₂S(O)₀₋₂, or CH₂C(O); L₂ = bond, (un)substituted CH₂, CH₂CH₂, O, NH, C(O), S(O)₀₋₂, CH₂C(O), C(O)CH₂, CH₂O, OCH₂, CH₂NH, NHCH₂, CH₂S(O)₀₋₂, S(O)₀₋₂CH₂, C(O)O, OC(O), C(O)NH, NHC(O), S(O)NH, S(O)NH₂, NHS(O), or NHS(O)₂; A = (un)substituted C₃₋₁₀ carbocycle or 5- to 12-membered heterocycle with 1-4 N/O/S(O)₀₋₂ heteroatoms; B = (un)substituted alk(en/yn)yl, C₃₋₁₀ carbocycle, or 5- to 12-membered heterocycle with 1-4 N/O/S(O)₀₋₂ heteroatoms; X = (independently) (un)substituted CH or N]. I are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, the invention relates to compds. that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compns. comprising I, and methods of treating thromboembolic and/or inflammatory disorders using I. I had K_i values of ≤ 15 μM in assays for Factor XIa and plasma kallikrein, thereby confirming their utility as effective inhibitors of these entities. Approx. 115 compds. I and various intermediates were prepared For instance, 5-cyanoindole was reduced to 5-cyanoindoline with NaBH₃CN (40%) or with Et₃SiH (77%). Then, Suzuki coupling of 2-IC₆H₄CO₂Me with 2-OCHC₆H₄B(OH)₂

gave 83% 2-OCHC6H4-C6H4CO2Me-2, which underwent reductive alkylation with 5-cyanoindoline (86%). The obtained 1-substituted 5-cyanoindoline was converted to the corresponding 5-amidoxime, which was reduced by Zn in AcOH to give the 5-amidine (18.5%). Alkaline saponification of the ester moiety gave

invention compound II, isolated as the bis(trifluoroacetate) salt.


IT 787631-36-1P, 2'-(5-Carbamoyl-2,3-dihydroindol-1-ylmethyl)-5'-
 [(3-chlorophenethyl)carbamoyl]-4-methoxybiphenyl-2-carboxylic acid
 787631-37-2P, 5'-(Benzylcarbamoyl)-2'-(5-carbamoyl-2,3-
 dihydroindol-1-ylmethyl)-4-methoxybiphenyl-2-carboxylic acid
 787631-38-3P, 2'-[5-(Aminomethyl)-3-benzylindol-1-ylmethyl]-4-
 methyl-5'-(methylcarbamoyl)biphenyl-2-carboxylic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of biarylmethyl indolines, indoles, and
 tetrahydroquinolines as serine protease inhibitors and anticoagulants)


RN 787631-36-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid,
 2'-[[5-(aminocarbonyl)-2,3-dihydro-1H-indol-1-yl]methyl]-5'-[[[2-(3-
 chlorophenyl)ethyl]amino]carbonyl]-4-methoxy- (CA INDEX NAME)



RN 787631-37-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxylic acid,
 2'-[[5-(aminocarbonyl)-2,3-dihydro-1H-indol-1-yl]methyl]-4-methoxy-5'-
 [[(phenylmethyl)amino]carbonyl]- (CA INDEX NAME)



RN 787631-38-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid,
 2'-[[5-(aminomethyl)-3-(phenylmethyl)-1H-indol-1-yl]methyl]-4-methyl-5'-

[(methylamino)carbonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 10:43:36 ON 06 OCT 2011